Aortic stenosis (AS) is the most common heart valve disease and its prevalence is increasing every year as a result of the aging of the population. Replacement of the native aortic valve is the definitive treatment method for severe symptomatic AS. For many years, surgical aortic valve replacement (SAVR) was the only available treatment method. The development of minimally invasive surgery and percutaneous aortic valve implantation revolutionized the treatment of patients with severe AS. In the last decade, transcatheter aortic valve implantation (TAVI) has established as an effective therapeutic method in inoperable patients, patients with high and moderate operative risk, while recently the indications have been extended to patients with low operative risk. The minimal invasiveness of the procedure, advances in technique and the experience of the operator have enabled the rapid development and expansion of indications for TAVI. Every aortic valve replacement method carries risks and has a set of complications accompanied by their limitations. While data on the long-term clinical outcomes and durability of biological valves after SAVR are well known, the lack of data on the low-risk patient undergoing TAVI represents a major limitation to the application of the TAVI method in the low-risk patient. Further research and long-term follow-up of low-risk patients treated with TAVI leave space for further expanding the indications and shifting the paradigm in the treatment of patients with severe aortic stenosis.